April 2022 FDA Recall Travoprost Ophthalmic Solution, 0.004% by Mylan Pharmaceuticals Inc
D-0748-2022 - Subpotent Drug and Failed Impurities/Degradation Specifications

This Class II drug recall was voluntarily initiated by Mylan Pharmaceuticals Inc on April 1, 2022 for the product Travoprost Ophthalmic Solution, 0.004%. The FDA reported the reason for recall as subpotent drug and failed impurities/degradation specifications. The product was distributed Nationwide and the recall is currently terminated.

Recall Number: D-0748-2022

Reason for Recall
Subpotent Drug and Failed Impurities/Degradation Specifications: low out-of-specification results obtained for assay and high out-of-specification results for related substance impurities/degradation during routine stability testing.
Initiated
04-01-2022
Reported
04-13-2022
Quantity
20,112 bottles

Recall Profile & Regulatory Data

Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Mylan Pharmaceuticals Inc
Nationwide in the USA and Puerto Rico
Travoprost Ophthalmic Solution, USP, 0.004%, 2.5 mL bottle, Rx only, Manufactured for: Mylan Pharmaceuticals Inc., Morgantown, WV 26505, NDC 0378-9651-32.

Batch or Lot Expiration Information

Lot# TV11W101, Exp Mar 2023